Amylyx Pharmaceuticals, Inc.

NASDAQ:AMLX

Biotechnology

Healthcare
$26.62 +0.93%

+$0.14 today

Market cap
$3.42B
Beta
-0.16
P/E (TTM)
-11.3
EPS (TTM)
-$1.36
52W Low $4.80High $18.61

Volume 1.51M

Average 1.21M

AMLX Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Amylyx Pharmaceuticals, Inc.NASDAQ: AMLX

Operating Margin · Q3 FY2026 · quarter ended Sep 2026

Operating margin not reported for Q3 FY2026

Context

  • Operating margin widened in 1 of the last 2 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMSep 2026
—— YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2024
-360.2%
Year-over-year change
-370.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How AMLX compares with its peers on the latest reported figures

AMLX Competitors Peer median
Operating Margin for AMLX and competitors
Company Period LTM level YoY 3-year change
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-58.9% -30.2 pp+29.4 pp
PRTAProthena Corporation plcLTM Mar 2026-217.9% -117.5 pp-1661.8 pp
ACIUAC Immune S.A.LTM Mar 2026-1749.0% -1566.4 pp-126.9 pp
DNLIDenali Therapeutics Inc.LTM Jun 2026-15058.2% ——
CLNNClene Inc.LTM Mar 2026-15535.1% -7553.1 pp-1307.0 pp
AMLXAmylyx Pharmaceuticals, Inc.FY2025— ——
PRAXPraxis Precision Medicines, Inc.FY2025— ——
ELDNEledon Pharmaceuticals, Inc.FY2025— ——
AVXLAnavex Life Sciences Corp.FY2025— ——
PMNProMIS Neurosciences, Inc.FY2025— ——
Peer median (excluding AMLX) -1749.0%-841.9 pp-717.0 pp

Competitors are the stored peer set for AMLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue022.23M380.79M87.37M0
Cost of Revenue02.99M25.44M42.16M525K
Gross Profit019.24M355.35M45.22M(525K)
Gross Margin—86.5%93.3%51.8%—
Research & Development44.04M93.45M128.19M104.08M90.4M
Selling, General & Admin38.93M127.13M188.36M114.33M62.89M
Operating Expenses82.69M220.58M316.54M359.95M152.77M
Depreciation & Amortization52K487K1.09M904K525K
EBITDA(87.88M)(197.11M)55.39M(290.98M)(144.16M)
EBITDA Margin—-886.7%14.5%-333.0%—
Operating Income(82.69M)(201.34M)38.8M(314.73M)(153.29M)
Operating Margin—-905.7%10.2%-360.2%—
Interest Income36K4.29M16.16M13.81M9.3M
Interest Expense00000
Other Income / Expenses(5.24M)3.74M15.5M12.6M8.6M
Income Before Tax(87.93M)(197.6M)54.3M(302.14M)(144.69M)
Pre-Tax Margin—-888.9%14.3%-345.8%—
Income Tax Expense0774K5.03M(393K)46K
Net Income(87.93M)(198.38M)49.27M(301.74M)(144.74M)
Net Margin—-892.4%12.9%-345.4%—
EPS (Basic)(1.52)(2.98)0.73(4.43)(1.53)
EPS (Diluted)(1.52)(2.98)0.70(4.43)(1.53)
Weighted Avg Shares57.86M66.51M67.23M68.14M94.57M
Weighted Avg Shares (Diluted)57.86M66.51M69.99M68.14M94.57M

Amylyx Pharmaceuticals, Inc.

NASDAQ:AMLX

Intrinsic Alpha fair value

Locked

Current Price

$26.62

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.